Aberrant cellular immune responses in humans infected persistently with parvovirus B19

Journal of Medical Virology

Volumn 78, Issue 1, 2006, Pages 129-133

  Isa, Adiba ^a   Norbeck, Oscar ^a   Hirbod, Taha ^a   Lundqvist, Anders ^a,b   Kasprowicz, Victoria ^c,d   Bowness, Paul ^c   Klenerman, Paul ^d   Broliden, Kristina ^a   Tolfvenstam, Thomas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BORÅS HOSPITAL   (Sweden)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cellular immunity; Erythrovirus; T lymphocyte responses; Viral persistence

Indexed keywords

STRUCTURAL PROTEIN;

ADULT; ALTERNATIVE RNA SPLICING; ANTIGENICITY; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; MALE; PARVOVIRUS; PERSISTENT VIRUS INFECTION; SEROCONVERSION; VIRUS CAPSID; VIRUS DETECTION; VIRUS GENOME;

ADULT; AGED; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON TYPE II; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

ERYTHROVIRUS; MIRIDAE; PARVOVIRUS;

EID: 28944443290     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20514     Document Type: Article

References (26)

1. Cassinotti P, Schultze D, Schlageter P, Chevili S, Siegl G. 1993. Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient. Eur J Clin Microbiol Infect Dis 12:701-704.
2. Faden H, Gary GW, Jr., Anderson LJ. 1992. Chronic parvovirus infection in a presumably immunologically healthy woman. Clin Infect Dis 15:595-597.
3. Franssila R, Hokynar K, Hedman K. 2001. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19. J Infect Dis 183:805-809.
4. Heegaard ED, Brown KE. 2002. Human parvovirus B19. Clin Microbiol Rev 15:485-505.
5. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. 2002. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol 40:933-936.
6. Kakimi K, Isogawa M, Chung J, Sette A, Chisari FV. 2002. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: Implications for immunotherapy of persistent viral infections. J Virol 76:8609-8620.
7. Klenerman P, Tolfvenstam T, Price DA, Nixon DF, Broliden K, Oxenius A. 2002. T lymphocyte responses against human parvovirus B19: Small virus, big response. Pathol Biol (Paris) 50:317-325.
8. Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, McMichael AJ, Cox WI, Steinman RM, Nixon D, Bhardwaj N. 1999. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive indiviuals. Aids 13:767-777.
9. Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, Tolfvenstam T. 2005. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 41:1201-1203.
10. Lundqvist A, Tolfvenstam T, Bostic J, Soderlund M, Broliden K. 1999a. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis 31:11-16.
11. Lundqvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. 1999b. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis 31:119-122.
12. Musiani M, Manaresi E, Gallinella G, Venturoli S, Zuffi E, Zerbini M. 2000. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol 60:347-352.
13. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, Chesnut R, Person JL, Redeker AG, et al. 1993. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:4659-4671.
14. Norbeck O, Isa A, Pohlmann C, Broliden K, Kasprowicz V, Bowness P, Klenerman P, Tolfvenstam T. 2005. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 79:12117-12121.
15. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. 1991. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174:1565-1570.
16. Probst HC, Tschannen K, Gallimore A, Martinic M, Basler M, Dumrese T, Jones E, van den Broek MF. 2003. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol 171:5415-5422.
17. Rehermann B. 2000. Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury. J Exp Med 191:1263-1268.
18. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047-1058.
19. Sasaki T, Murai C, Muryoi T, Takahashi Y, Munakata Y, Sugamura K, Abe K. 1995. Persistent infection of human parvovirus B19 in a normal subject. Lancet 346:851.
20. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. 2002. Genetic diversity within human erythroviruses: Identification of three genotypes. J Virol 76:9124-9134.
21. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR. 1986. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 58:921-936.
22. Tolfvenstam T, Lundqvist A, Levi M, Wahren B, Broliden K. 2000. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins. Vaccine 19:758-763.
23. Tolfvenstam T, Oxenius A, Price DA, Shacklett BL, Spiegel HM, Hedman K, Norbeck O, Levi M, Olsen K, Kantzanou M, Nixon DF, Broliden K, Klenerman P. 2001. Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol 75:540-543.
24. von Poblotzki A, Hemauer A, Gigler A, Puchhammer-Stockl E, Heinz FX, Pont J, Laczika K, Wolf H, Modrow S. 1995. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: Implications for pathogenesis. J Infect Dis 172:1356-1359.
25. Weigel-Kelley KA, Yoder MC, Srivastava A. 2003. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: Requirement of functional activation of beta1 integrin for viral entry. Blood 102:3927-3933.
26. Zuffi E, Manaresi E, Gallinella G, Gentilomi GA, Venturoli S, Zerbini M, Musiani M. 2001. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 14:151-158.